Alzheimer’s drug Leqembi can be seen in this undated handout picture obtained by Reuters on January 20, 2023. Eisai | Reuters New Alzheimer’s antibody treatment Leqembi could cost Medicare up to $5 billion a year, according to a study published this week in a leading medical journal. Medicare would spend about $2 billion a year …
Continue reading “Leqembi might value Medicare $5 billion a 12 months”